Journal article
Clinical Outcome of Prostate Cancer Patients with Germline DNA Repair Mutations: Retrospective Analysis from an International Study
J Mateo, HH Cheng, H Beltran, D Dolling, W Xu, CC Pritchard, H Mossop, P Rescigno, R Perez-Lopez, V Sailer, M Kolinsky, A Balasopoulou, C Bertan, DM Nanus, ST Tagawa, H Thorne, B Montgomery, S Carreira, S Sandhu, MA Rubin Show all
European Urology | ELSEVIER SCIENCE BV | Published : 2018
Abstract
Background: Germline DNA damage repair gene mutation (gDDRm) is found in >10% of metastatic prostate cancer (mPC). Their prognostic and predictive impact relating to standard therapies is unclear. Objective: To determine whether gDDRm status impacts benefit from established therapies in mPC. Design, setting, and participants: This is a retrospective, international, observational study. Medical records were reviewed for 390 mPC patients with known gDDRm status. All 372 patients from Royal Marsden (UK), Weill-Cornell (NY), and University of Washington (WA) were previously included in a prevalence study (Pritchard, NEJM 2016); the remaining 18 were gBRCA1/2m carriers, from the kConFab consortiu..
View full abstractRelated Projects (2)
Grants
Awarded by National Cancer Institute
Funding Acknowledgements
This work was supported by a Stand Up To Cancer-Prostate Cancer Foundation Prostate Dream Team Translational Cancer Research Grant. Stand Up To Cancer is a program of the Entertainment Industry Foundation administered by the American Association for Cancer Research (SU2C-AACR-DT0712). We also acknowledge support from Movember and Prostate Cancer UK, and from the KConFab consortium (Kathleen Cuningham Foundation Consortium for research into familial breast cancer; Australia) for providing data for this report. J. Mateo, H. Cheng, H. Beltran, and C. Pritchard were supported by Prostate Cancer Foundation Young Investigator Awards. We also acknowledge funding support from NIH/NCI (P50CA097186), the Institute for Prostate Cancer Research (Seattle, WA, USA), a Medical Research Council-Prostate Cancer UK fellowship (J. Mateo), an Experimental Cancer Medical Centre grant, and a Biomedical Research Centre grant to the ICR/Royal Marsden. S. Sandhu was supported by a Prostate Cancer Foundation of Australia Young Investigator Award.